Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;39(2):e153-e154.
doi: 10.1111/jdv.20197. Epub 2024 Jun 24.

Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023

Hannah Godfrey  1 , Zachary Leibovit-Reiben  1 , Patrick Jedlowski  2 , Rebecca Thiede  2
Affiliations

Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023

Hannah Godfrey et al. J Eur Acad Dermatol Venereol. 2025 Feb.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Alhanshali L, Buontempo M, Shapiro J, Lo Sicco K. Medication‐induced hair loss: an update. J Am Acad Dermatol. 2023;89(2S):S20–S28.
    1. Mounessa J, Caravaglio JV, Domozych R, Chapman S, Dellavalle RP, Dunnick CA, et al. Commonly prescribed medications associated with alopecia. J Am Acad Dermatol. 2023;88(6):1326–1337.e2.
    1. Research C for DE and July – September 2023 | Potential signals of serious risks/new safety information identified by the FDA adverse event reporting system (FAERS). FDA [Internet]. 2024 Jan 2 [cited 2024 Jan 9]; Available from: https://www.fda.gov/drugs/questions‐and‐answers‐fdas‐adverse‐event‐repor...
    1. Adhikari R, Jha K, Dardari Z, Heyward J, Blumenthal RS, Eckel RH, et al. National Trends in use of sodium‐glucose Cotransporter‐2 inhibitors and glucagon‐like Peptide‐1 receptor agonists by cardiologists and other specialties, 2015 to 2020. J Am Heart Assoc. 2022;11(9):e023811.
    1. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP‐1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS‐1): a double‐blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–155.

LinkOut - more resources